Member Info for SlamDunk1

AVA6103 trial record uploaded:

https://clinicaltrials.gov/study/NCT07454642?term=avacta&rank=1

“Chris and her brilliant team continue to build and protect the IP of #AVCT in order to exploit the full value of preCISION for shareholders. honoured to sit on the board of such a disruptive biotech. 2026 will be a transformational year for us all”

https://x.com/hughesy0707/status/2013909360804590069?s=46&t=gxfb-KkHLvabwUnYcuiOpA

Up and recruiting in 4 sites so far:

- 3 sites in the US

- 1 site in the UK

https://clinicaltrials.gov/study/NCT06999603?term=synairgen&rank=1

Already posted, apologies

"In our view, the amended CB terms indicate management confidence in their ability to secure funds to advance Avacta’s pre|CISION assets through clinical development. This funding is likely to come from a variety of sources including partnerships, strategic investment, and/or an equity raise, and could be catalysed by key data readouts slated for the next 12 months: Phase I FAP-Dox SGC results in H225 (potentially at ESMO 2025) and TNBC data in H126. Appetite for Avacta equity has been demonstrated through the two recent oversubscribed equity placings; notably the proceeds being used to cash settle CB repayments has also resulted in less dilution than would have been the case with a direct equity settlement. CB amendments announced in tandem with this latest raise allow deferral of the next two quarterly repayments removing some pressure from near-term cash flow requirements. Subject to extending Avacta’s cash runway beyond Q126, there are multiple opportunities to unlock value through generating and developing a pipeline of highly novel tumour targeting drug conjugates. Our last published Avacta valuation is £449m ($561m)."

https://www.trinitydelta.org/research-notes/cb-amendment-creates-funding-solution-optionality/

" Initial data in expansion cohorts late in 2025 in SGC, HG-STS and triple negative breast cancer"

Does this mean the data release for TNBC has been brought forward from early 2026 to 2025?

W-8BEN form.

Yes you could tell, very poor.

Links dont work as they are but just copy and paste into the search bar.

Probably already shared but some abstracts below:

2699 / 16 - Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insights

https://www.abstractsonline.com/pp8/#!/20273/presentation/5420

3139 / 24 - The novel peptide drug conjugate AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage

https://www.abstractsonline.com/pp8/#!/20273/presentation/3042

CT151 / 17 - Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates

Still embargoed.

Thanks Jint. Appreciate the pre-amble notes. I wrote down Ch.2, have you double checked with the slides?

Apologies if a false alarm - noticed yesterdays date and rushed to do the side by side without checking the dates!

Updated yesterday:

https://clinicaltrials.gov/study/NCT04969835?term=avacta&rank=1&tab=history&a=7&b=8&compareMode=sideBySide#version-content-panel

For anyone interested, they have been filed at Companies House:

https://find-and-update.company-information.service.gov.uk/company/05233429/filing-history

Mani,

They have only recently received approval from the HRA / MHRA which is noted in the editorial notes at the bottom.

They are still waiting ethics approval from REC via the HRA.

Therefore, it is unlikely they have received full approval yet.

Https://www.isrctn.com/ISRCTN30482473

I was able to vote through iWeb using the chat function. I have to do it this way for the agm resolutions as well.

Https://www.proactiveinvestors.co.uk/companies/news/1063256/synairgen-ceo-on-funding-critical-phase-2-trial-for-sng001-1063256.html

May be of interest to some. Could infer that a combo of AVA6000 & Interferon in TNBC could counteract the effects of OSM and increase efficacy of chemo.

https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-024-01918-2#Sec25

Mani

You're not really making a point here but anyway, we should get an EGM and hopefully that is on the back of a whopper RNS.